UK health authorities have issued a precautionary recall of a blood pressure medication after a packaging error that could expose patients to dangerously high doses. The Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall of Crescent Pharma Limited Ramipril 2.5mg capsules following reports that some packages contained incorrectly labelled blister strips.
Ramipril Dosing Error Risk Assessment
Potential patient impact from mislabelled medication strips
dose
dose
risk
Source: MHRA, 2024 | Georgian Medical Journal News
Specific Batch Affected by Manufacturing Error
The recall specifically targets batch number GR155023 of Crescent Pharma Limited Ramipril 2.5mg capsules. According to the MHRA announcement, some blister strips inside these packages are incorrectly labelled as containing 10mg ramipril instead of the prescribed 2.5mg dose.
Patients taking ramipril are advised to immediately check their medication packaging for the affected batch number. Those who identify the problematic batch should contact their pharmacy or healthcare provider for guidance on replacement medication and monitoring requirements.
Patient Safety Implications of Dosing Error
Ramipril belongs to a class of medications called ACE inhibitors, commonly prescribed for hypertension and heart failure management. Taking a dose four times higher than prescribed could lead to severe hypotension, dizziness, and potential cardiovascular complications.
The World Health Organization identifies medication errors as a leading cause of preventable patient harm globally. Packaging and labelling errors represent a critical safety concern that requires immediate manufacturer response and regulatory oversight.
Regulatory Response and Industry Standards
This recall highlights ongoing challenges in pharmaceutical quality control systems. The MHRA’s rapid response demonstrates the importance of robust pharmacovigilance systems in detecting and addressing medication safety issues before widespread patient harm occurs.
Crescent Pharma Limited has not yet issued a public statement regarding the root cause of the packaging error or corrective measures being implemented. The regulatory framework for drug recalls requires manufacturers to investigate quality failures and implement preventive measures to avoid recurrence.
Patients should immediately check ramipril packaging for batch GR155023 and contact their pharmacy if blister strips are labelled as 10mg instead of 2.5mg
— Medicines and Healthcare products Regulatory Agency (MHRA, 2024)
Key takeaways
- Crescent Pharma Ramipril 2.5mg capsules batch GR155023 may contain mislabelled 10mg strips
- Taking 10mg instead of 2.5mg could cause dangerous blood pressure drops and cardiovascular effects
- Affected patients should contact their pharmacy immediately for replacement medication and safety monitoring
Frequently asked questions
How can I identify if my medication is affected?
Check your ramipril package for the batch number GR155023 and examine blister strips inside for any labelled as 10mg. If found, do not take the medication and contact your pharmacy immediately.
What should I do if I’ve already taken mislabelled capsules?
Contact your healthcare provider or pharmacy immediately for medical guidance. Monitor for symptoms of low blood pressure including dizziness, lightheadedness, or fainting.
Will there be delays in getting replacement medication?
Pharmacies should be able to provide alternative ramipril products or contact your prescriber for temporary alternative medications while ensuring continuity of blood pressure management.
The MHRA continues to monitor this recall and work with Crescent Pharma Limited to ensure complete removal of affected batches from the supply chain. Healthcare providers are advised to counsel patients on proper medication verification and emphasize the importance of reporting any unusual packaging observations to prevent future safety incidents.
Was this article helpful?
Related Coverage
